

Supplemental Table 9. Biomarkers in Adjusted* Proportional Hazards Models of Time to Next Exacerbation*

Univariable Biomarker [†]	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness					
	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio
ENRAGE	0.30	0.10	1.35	0.003	1.10 to 1.65	0.30	0.10	1.34	0.004	1.10 to 1.64
MPO	0.26	0.10	1.30	0.008	1.07 to 1.57	0.28	0.10	1.32	0.006	1.08 to 1.61
SRAGE	0.20	0.09	1.23	0.021	1.03 to 1.46	0.25	0.10	1.29	0.009	1.06 to 1.55
ICAM1	0.38	0.16	1.46	0.021	1.06 to 2.02	0.22	0.09	1.24	0.014	1.04 to 1.47
NE	0.18	0.08	1.19	0.022	1.03 to 1.39	0.21	0.09	1.24	0.015	1.04 to 1.47
YKL40	0.23	0.10	1.26	0.024	1.03 to 1.53	0.34	0.15	1.41	0.020	1.06 to 1.88
TARC	1.00	0.46	2.72	0.031	1.10 to 6.74	0.18	0.08	1.19	0.022	1.03 to 1.39
MMP9	0.18	0.09	1.20	0.039	1.01 to 1.43	0.16	0.08	1.17	0.047	1.00 to 1.37
IL1 β	0.16	0.08	1.17	0.049	1.00 to 1.37	0.82	0.44	2.27	0.062	0.96 to 5.38
IL5	0.58	0.31	1.79	0.062	0.97 to 3.29	0.54	0.31	1.72	0.077	0.94 to 3.15
IL17A	0.28	0.17	1.32	0.098	0.95 to 1.83	0.28	0.16	1.32	0.091	0.96 to 1.82
S100A9	-0.20	0.12	0.82	0.12	0.645 to 1.05	0.17	0.10	1.19	0.092	0.97 to 1.45
IFN γ	0.37	0.26	1.44	0.16	0.861 to 2.41	0.34	0.26	1.40	0.19	0.84 to 2.34
PR3	0.12	0.09	1.13	0.19	0.94 to 1.36	0.29	0.25	1.34	0.24	0.82 to 2.19
IL8	0.30	0.25	1.36	0.23	0.823 to 2.23	-0.09	0.09	0.92	0.33	0.77 to 1.09
GMCSF	0.29	0.27	1.34	0.28	0.784 to 2.30	0.03	0.04	1.03	0.34	0.97 to 1.11
SLPI	-0.09	0.09	0.91	0.30	0.762 to 1.09	-0.11	0.14	0.90	0.43	0.69 to 1.17
Calprotectin	0.03	0.04	1.03	0.34	0.966 to 1.11	-0.11	0.17	0.90	0.53	0.65 to 1.25
IL10	0.09	0.15	1.10	0.54	0.817 to 1.47	0.19	0.32	1.21	0.55	0.64 to 2.29
S100A8	-0.06	0.14	0.94	0.67	0.709 to 1.25	0.09	0.15	1.09	0.58	0.80 to 1.47
TNF α	-0.04	0.12	0.96	0.74	0.765 to 1.21	-0.05	0.12	0.95	0.66	0.76 to 1.19
HMGB1	-0.06	0.17	0.95	0.75	0.677 to 1.32	-0.04	0.14	0.96	0.78	0.73 to 1.27
IL6	0.04	0.14	1.04	0.81	0.78 to 1.37	0.04	0.14	1.04	0.8	0.78 to 1.37
CRP	-0.04	0.19	0.96	0.84	0.662 to 1.40	0.06	0.36	1.07	0.86	0.53 to 2.15

124 * Adjusted by Age, Sex and Number of Prior Pulmonary Exacerbations.

125 † Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products
126 binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1
127 intracellular adhesion molecule 1; IFN γ interferon γ ; IL interleukin; MMP9 matrix metalloproteinase 9; MPO myeloperoxidase; NE
128 neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease
129 inhibitor; TARC thymus and activation regulation chemokine; TNF α tumor necrosis factor α ; YKL40 chitinase 3-like 1 protein.
130